JCI Insight (Nov 2023)

Anti–NF-κB peptide derived from nuclear acidic protein attenuates ovariectomy-induced osteoporosis in mice

  • Kenji Takami,
  • Kazuki Okamoto,
  • Yuki Etani,
  • Makoto Hirao,
  • Akira Miyama,
  • Gensuke Okamura,
  • Atsushi Goshima,
  • Taihei Miura,
  • Takuya Kurihara,
  • Yuji Fukuda,
  • Takashi Kanamoto,
  • Ken Nakata,
  • Seiji Okada,
  • Kosuke Ebina

Journal volume & issue
Vol. 8, no. 22

Abstract

Read online

NF-κB is a transcription factor that is activated with aging. It plays a key role in the development of osteoporosis by promoting osteoclast differentiation and inhibiting osteoblast differentiation. In this study, we developed a small anti–NF-κB peptide called 6A-8R from a nuclear acidic protein (also known as macromolecular translocation inhibitor II, Zn2+-binding protein, or parathymosin) that inhibits transcriptional activity of NF-κB without altering its nuclear translocation and binding to DNA. Intraperitoneal injection of 6A-8R attenuated ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation, promoting osteoblast differentiation, and inhibiting sclerostin production by osteocytes in vivo with no apparent side effects. Conversely, in vitro, 6A-8R inhibited osteoclast differentiation by inhibiting NF-κB transcriptional activity, promoted osteoblast differentiation by promoting Smad1 phosphorylation, and inhibited sclerostin expression in osteocytes by inhibiting myocyte enhancer factors 2C and 2D. These findings suggest that 6A-8R has the potential to be an antiosteoporotic therapeutic agent with uncoupling properties.

Keywords